195 related articles for article (PubMed ID: 28158205)
21. Identification and Evaluation of Olive Phenolics in the Context of Amine Oxidase Enzyme Inhibition and Depression: In Silico Modelling and In Vitro Validation.
Karagiannis TC; Ververis K; Liang JJ; Pitsillou E; Liu S; Bresnehan SM; Xu V; Wijoyo SJ; Duan X; Ng K; Hung A; Goebel E; El-Osta A
Molecules; 2024 May; 29(11):. PubMed ID: 38893322
[TBL] [Abstract][Full Text] [Related]
22. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.
Schmidt DM; McCafferty DG
Biochemistry; 2007 Apr; 46(14):4408-16. PubMed ID: 17367163
[TBL] [Abstract][Full Text] [Related]
23. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
[TBL] [Abstract][Full Text] [Related]
24. LSD1 in drug discovery: From biological function to clinical application.
Liu HM; Zhou Y; Chen HX; Wu JW; Ji SK; Shen L; Wang SP; Liu HM; Liu Y; Dai XJ; Zheng YC
Med Res Rev; 2024 Mar; 44(2):833-866. PubMed ID: 38014919
[TBL] [Abstract][Full Text] [Related]
25. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
[TBL] [Abstract][Full Text] [Related]
26. Post-translational modifications of lysine-specific demethylase 1.
Kim D; Nam HJ; Baek SH
Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194968. PubMed ID: 37572976
[TBL] [Abstract][Full Text] [Related]
27. Human histone demethylase LSD1 reads the histone code.
Forneris F; Binda C; Vanoni MA; Battaglioli E; Mattevi A
J Biol Chem; 2005 Dec; 280(50):41360-5. PubMed ID: 16223729
[TBL] [Abstract][Full Text] [Related]
28. Drug Design Concepts for LSD1-Selective Inhibitors.
Ota Y; Suzuki T
Chem Rec; 2018 Dec; 18(12):1782-1791. PubMed ID: 30277644
[TBL] [Abstract][Full Text] [Related]
29. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications.
Lee MG; Wynder C; Schmidt DM; McCafferty DG; Shiekhattar R
Chem Biol; 2006 Jun; 13(6):563-7. PubMed ID: 16793513
[TBL] [Abstract][Full Text] [Related]
30. Histone H3 peptide based LSD1-selective inhibitors.
Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
[TBL] [Abstract][Full Text] [Related]
31. Lysine-specific demethylase 1-selective inactivators: protein-targeted drug delivery mechanism.
Ogasawara D; Itoh Y; Tsumoto H; Kakizawa T; Mino K; Fukuhara K; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N; Suzuki T
Angew Chem Int Ed Engl; 2013 Aug; 52(33):8620-4. PubMed ID: 23824985
[No Abstract] [Full Text] [Related]
32. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
Kakizawa T; Ota Y; Itoh Y; Suzuki T
Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
[TBL] [Abstract][Full Text] [Related]
33. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.
Zheng YC; Yu B; Chen ZS; Liu Y; Liu HM
Epigenomics; 2016 May; 8(5):651-66. PubMed ID: 27102879
[TBL] [Abstract][Full Text] [Related]
34. A selective phenelzine analogue inhibitor of histone demethylase LSD1.
Prusevich P; Kalin JH; Ming SA; Basso M; Givens J; Li X; Hu J; Taylor MS; Cieniewicz AM; Hsiao PY; Huang R; Roberson H; Adejola N; Avery LB; Casero RA; Taverna SD; Qian J; Tackett AJ; Ratan RR; McDonald OG; Feinberg AP; Cole PA
ACS Chem Biol; 2014 Jun; 9(6):1284-93. PubMed ID: 24707965
[TBL] [Abstract][Full Text] [Related]
35. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
[TBL] [Abstract][Full Text] [Related]
37. LSD1 demethylates histone and non-histone proteins.
Nicholson TB; Chen T
Epigenetics; 2009 Apr; 4(3):129-32. PubMed ID: 19395867
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
[TBL] [Abstract][Full Text] [Related]
39. Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1.
Amano Y; Kikuchi M; Sato S; Yokoyama S; Umehara T; Umezawa N; Higuchi T
Bioorg Med Chem; 2017 May; 25(9):2617-2624. PubMed ID: 28336409
[TBL] [Abstract][Full Text] [Related]
40. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]